// App-Quantinova.ai

617 : HLA-DRB1*07:01 biomarker characterization of hepatotoxicity during lapatinib combination therapies in ALTTO.

Researchers

Presenter

  • Colin F. Spraggs

Principal Investigators

  • Liling Warren

  • Nicola Jackson

  • Julie Byrne

  • Michael Andersson

  • Masakazu Toi

  • Lyndsay Harris

  • Julie Gralow

  • Rocco Crescenzo

  • Dana Fraser

  • Zefei Jiang

  • Zeba Aziz

  • Zhongsheng Tong

  • Shun Devan Moodley

  • Ajay O. Mehta

  • Alison A. Armour

  • Lisa Simone Williams

  • Linda P Briley

Medical Centers

  • Tianjin Cancer Hospital, Tianjin, China

  • Hameed Latif Hospital, Lahore, Pakistan

  • Kyoto University, Kyoto, Japan

  • Rigshospitalet, Copenhagen, Denmark

  • GlaxoSmithKline, Collegeville, PAUniversity of Witwatersrand, Parktown, South AfricaGlaxoSmithKline, London, United Kingdom

  • UH Cleveland Medical Center, Cleveland, OH

  • University of Washington, Seattle, WA

  • Central India Cancer Research Institute, Nagpur, India

  • GlaxoSmithKline, Raleigh-Durham, NC

  • The Hospital Affiliated to Military Medical Science, Beijing, China

  • GlaxoSmithKline, Stevenage, United Kingdom.

Locations

  • China

  • Japan

  • United Kingdom

  • United States

  • Pakistan

  • India

  • Denmark

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Alanine transaminase

  • Circulating tumor cells

  • Major histocompatibility complex, class II, DR beta 1

Drug/Treatment

  • Lapatinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved